Efficacy of postoperative hepatic arterial infusion chemotherapy with CDDP for hepatocellular carcioma with early recurrence risk factors. - adjubant CDDP TAI for HCC with high recurrence risk factors.

Department of Gastroenterology and Metabolism,Hiroshima University Hospital0 个研究点目标入组 60 人开始时间: 2013年10月15日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients with mixed hepatocellular and cholangiocellular carcinoma diagnosed by histologial examination 2) Severe arterio-portal or arterio-venous shunts in the liver 3) Patinets with difficulty with drug arrival to hepatic lesion 4) Other uncontrolled severe illness a. With severe cardiac failure b. With severe renal function disease c. With active infectious disease except viral hepatitis d. With active gastrointestinal hemorrhage e. With active other malignancies f. With hepatic encephalopathy and severe mental disorder g. With clinically significant refractory ascites or pleural effusion 5) Allergic reaction to iodine contrast material, gadolinium contrast material, or platium containing agent. 6)Patients medicated with steroid 7) A pregnant woman, or a woman suspected of pregnancy. 8) Patients who are concluded to be inappropriate to participate in this study by their physitians

发起方

Department of Gastroenterology and Metabolism,Hiroshima University Hospital